Stableford Capital II LLC Decreases Holdings in Abbott Laboratories $ABT

Stableford Capital II LLC cut its stake in Abbott Laboratories (NYSE:ABT) by 54.6% during the 2nd quarter, HoldingsChannel reports. The firm owned 6,098 shares of the healthcare product maker’s stock after selling 7,343 shares during the quarter. Stableford Capital II LLC’s holdings in Abbott Laboratories were worth $553,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Stonebridge Financial Group LLC boosted its position in Abbott Laboratories by 28.2% in the 2nd quarter. Stonebridge Financial Group LLC now owns 49,984 shares of the healthcare product maker’s stock valued at $4,536,000 after buying an additional 10,990 shares during the last quarter. Somerset Trust Co lifted its stake in shares of Abbott Laboratories by 1.0% in the second quarter. Somerset Trust Co now owns 46,025 shares of the healthcare product maker’s stock worth $4,176,000 after acquiring an additional 458 shares in the last quarter. Dogwood Wealth Management LLC boosted its holdings in Abbott Laboratories by 25.7% in the second quarter. Dogwood Wealth Management LLC now owns 611 shares of the healthcare product maker’s stock valued at $55,000 after purchasing an additional 125 shares during the last quarter. Burkett Financial Services LLC grew its stake in Abbott Laboratories by 21.1% during the 2nd quarter. Burkett Financial Services LLC now owns 1,428 shares of the healthcare product maker’s stock valued at $130,000 after purchasing an additional 249 shares in the last quarter. Finally, CX Institutional increased its holdings in Abbott Laboratories by 17.8% during the 2nd quarter. CX Institutional now owns 94,489 shares of the healthcare product maker’s stock worth $8,574,000 after purchasing an additional 14,257 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 1.4%

ABT stock opened at $105.58 on Wednesday. The firm has a market cap of $182.69 billion, a price-to-earnings ratio of 34.17, a PEG ratio of 2.07 and a beta of 0.59. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The firm has a fifty day moving average price of $94.23 and a two-hundred day moving average price of $100.20. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same period last year, the firm posted $1.26 EPS. The company’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s payout ratio is presently 81.55%.

Wall Street Analysts Forecast Growth

ABT has been the subject of a number of recent analyst reports. Robert W. Baird assumed coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target for the company. BTIG Research raised their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Leerink Partners dropped their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research report on Tuesday, April 21st. Stifel Nicolaus reduced their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Finally, Argus decreased their price target on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $118.17.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.